{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T13:17:59Z","timestamp":1795180679999,"version":"4.10.3"},"reference-count":45,"publisher":"American Association for Cancer Research (AACR)","issue":"9","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2008,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Overexpression of the prosurvival Bcl-2 family members (Bcl-2, Bcl-xL, and Mcl-1) is commonly associated with tumor maintenance, progression, and chemoresistance. We previously reported the discovery of ABT-737, a potent, small-molecule Bcl-2 family protein inhibitor. A major limitation of ABT-737 is that it is not orally bioavailable, which would limit chronic single agent therapy and flexibility to dose in combination regimens. Here we report the biological properties of ABT-263, a potent, orally bioavailable Bad-like BH3 mimetic (Ki's of &amp;lt;1 nmol\/L for Bcl-2, Bcl-xL, and Bcl-w). The oral bioavailability of ABT-263 in preclinical animal models is 20% to 50%, depending on formulation. ABT-263 disrupts Bcl-2\/Bcl-xL interactions with pro-death proteins (e.g., Bim), leading to the initiation of apoptosis within 2 hours posttreatment. In human tumor cells, ABT-263 induces Bax translocation, cytochrome c release, and subsequent apoptosis. Oral administration of ABT-263 alone induces complete tumor regressions in xenograft models of small-cell lung cancer and acute lymphoblastic leukemia. In xenograft models of aggressive B-cell lymphoma and multiple myeloma where ABT-263 exhibits modest or no single agent activity, it significantly enhances the efficacy of clinically relevant therapeutic regimens. These data provide the rationale for clinical trials evaluating ABT-263 in small-cell lung cancer and B-cell malignancies. The oral efficacy of ABT-263 should provide dosing flexibility to maximize clinical utility both as a single agent and in combination regimens. [Cancer Res 2008;68(9):3421\u20138]<\/jats:p>","DOI":"10.1158\/0008-5472.can-07-5836","type":"journal-article","created":{"date-parts":[[2008,5,1]],"date-time":"2008-05-01T21:11:48Z","timestamp":1209676308000},"page":"3421-3428","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":1861,"title":["ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor"],"prefix":"10.1158","volume":"68","author":[{"given":"Christin","family":"Tse","sequence":"first","affiliation":[{"name":"Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander R.","family":"Shoemaker","sequence":"additional","affiliation":[{"name":"Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Adickes","sequence":"additional","affiliation":[{"name":"Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark G.","family":"Anderson","sequence":"additional","affiliation":[{"name":"Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Chen","sequence":"additional","affiliation":[{"name":"Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sha","family":"Jin","sequence":"additional","affiliation":[{"name":"Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric F.","family":"Johnson","sequence":"additional","affiliation":[{"name":"Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kennan C.","family":"Marsh","sequence":"additional","affiliation":[{"name":"Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Mitten","sequence":"additional","affiliation":[{"name":"Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Nimmer","sequence":"additional","affiliation":[{"name":"Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Roberts","sequence":"additional","affiliation":[{"name":"Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen K.","family":"Tahir","sequence":"additional","affiliation":[{"name":"Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Xiao","sequence":"additional","affiliation":[{"name":"Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiufen","family":"Yang","sequence":"additional","affiliation":[{"name":"Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haichao","family":"Zhang","sequence":"additional","affiliation":[{"name":"Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Fesik","sequence":"additional","affiliation":[{"name":"Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saul H.","family":"Rosenberg","sequence":"additional","affiliation":[{"name":"Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven W.","family":"Elmore","sequence":"additional","affiliation":[{"name":"Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2008,5,1]]},"reference":[{"key":"2022061700424228400_B1","doi-asserted-by":"crossref","unstructured":"Hanahan D, Weinberg RA. The hallmarks of cancer. Cell\u20082000; 100: 57\u201370.","DOI":"10.1016\/S0092-8674(00)81683-9"},{"key":"2022061700424228400_B2","doi-asserted-by":"crossref","unstructured":"Danial NN, Korsmeyer SJ. Cell death: critical control points. Cell\u20082004; 116: 205\u201319.","DOI":"10.1016\/S0092-8674(04)00046-7"},{"key":"2022061700424228400_B3","doi-asserted-by":"crossref","unstructured":"Fesik SW. Promoting apoptosis as a strategy for cancer drug discovery. Nat Rev Cancer\u20082005; 5: 876\u201385.","DOI":"10.1038\/nrc1736"},{"key":"2022061700424228400_B4","doi-asserted-by":"crossref","unstructured":"Petros AM, Dinges J, Augeri DJ, et al. Discovery of a potent inhibitor of the antiapoptotic protein Bcl-xL from NMR and parallel synthesis. J Med Chem\u20082006; 49: 656\u201363.","DOI":"10.1021\/jm0507532"},{"key":"2022061700424228400_B5","doi-asserted-by":"crossref","unstructured":"Park CM, Oie T, Petros AM, et al. Design, synthesis, and computational studies of inhibitors of Bcl-XL. J Am Chem Soc\u20082006; 128: 16206\u201312.","DOI":"10.1021\/ja0650347"},{"key":"2022061700424228400_B6","doi-asserted-by":"crossref","unstructured":"Bruncko M, Oost TK, Belli BA, et al. Studies leading to potent, dual inhibitors of Bcl-2 and Bcl-xL. J Med Chem\u20082007; 50: 641\u201362.","DOI":"10.1021\/jm061152t"},{"key":"2022061700424228400_B7","doi-asserted-by":"crossref","unstructured":"Chen S, Dai Y, Harada H, Dent P, Grant S. Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation. Cancer Res\u20082007; 67: 782\u201391.","DOI":"10.1158\/0008-5472.CAN-06-3964"},{"key":"2022061700424228400_B8","doi-asserted-by":"crossref","unstructured":"Kuroda J, Kimura S, Strasser A, et al. Apoptosis-based dual molecular targeting by INNO-406, a second-generation Bcr-Abl inhibitor, and ABT-737, an inhibitor of antiapoptotic Bcl-2 proteins, against Bcr-Abl-positive leukemia. Cell Death Differ\u20082007; 14: 1667\u201377.","DOI":"10.1038\/sj.cdd.4402168"},{"key":"2022061700424228400_B9","doi-asserted-by":"crossref","unstructured":"Kohl TM, Hellinger C, Ahmed F, et al. BH3 mimetic ABT-737 neutralizes resistance to FLT3 inhibitor treatment mediated by FLT3-independent expression of BCL2 in primary AML blasts. Leukemia\u20082007; 8: 1763\u201372.","DOI":"10.1038\/sj.leu.2404776"},{"key":"2022061700424228400_B10","doi-asserted-by":"crossref","unstructured":"Kang MH, Kang YH, Szymanska B, et al. Activity of vincristine, L-ASP, and dexamethasone against acute lymphoblastic leukemia is enhanced by the BH3-mimetic ABT-737 in vitro and in vivo. Blood\u20082007; 110: 2057\u201366.","DOI":"10.1182\/blood-2007-03-080325"},{"key":"2022061700424228400_B11","doi-asserted-by":"crossref","unstructured":"Tahir SK, Yang X, Anderson MG, et al. Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737. Cancer Res\u20082007; 67: 1176\u201383.","DOI":"10.1158\/0008-5472.CAN-06-2203"},{"key":"2022061700424228400_B12","doi-asserted-by":"crossref","unstructured":"Oltersdorf T, Elmore SW, Shoemaker AR, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature\u20082005; 435: 677\u201381.","DOI":"10.1038\/nature03579"},{"key":"2022061700424228400_B13","doi-asserted-by":"crossref","unstructured":"Konopleva M, Contractor R, Tsao T, et al. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell\u20082006; 10: 375\u201388.","DOI":"10.1016\/j.ccr.2006.10.006"},{"key":"2022061700424228400_B14","doi-asserted-by":"crossref","unstructured":"van Delft MF, Wei AH, Mason KD, et al. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak\/Bax if Mcl-1 is neutralized. Cancer Cell\u20082006; 10: 389\u201399.","DOI":"10.1016\/j.ccr.2006.08.027"},{"key":"2022061700424228400_B15","doi-asserted-by":"crossref","unstructured":"Trudel S, Stewart AK, Li Z, et al. The Bcl-2 family protein inhibitor, ABT-737, has substantial antimyeloma activity and shows synergistic effect with dexamethasone and melphalan. Clin Cancer Res\u20082007; 13: 621\u20139.","DOI":"10.1158\/1078-0432.CCR-06-1526"},{"key":"2022061700424228400_B16","doi-asserted-by":"crossref","unstructured":"Kline MP, Rajkumar SV, Timm MM, et al. ABT-737, an inhibitor of Bcl-2 family proteins, is a potent inducer of apoptosis in multiple myeloma cells. Leukemia\u20082007; 21: 1549\u201360.","DOI":"10.1038\/sj.leu.2404719"},{"key":"2022061700424228400_B17","doi-asserted-by":"crossref","unstructured":"Del Gaizo Moore V, Brown JR, Certo M, Love TM, Novina CD, Letai A. Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. J Clin Invest\u20082007; 117: 112\u201321.","DOI":"10.1172\/JCI28281"},{"key":"2022061700424228400_B18","unstructured":"Bruncko M, Ding H, Elmore SW, et al. Apoptosis promoters. U.S. Patent application: U.S. 20070027135. Published Feb. 1, 2007."},{"key":"2022061700424228400_B19","doi-asserted-by":"crossref","unstructured":"Zhang H, Nimmer P, Rosenberg SH, Ng SC, Joseph M. Development of a high-throughput fluorescence polarization assay for Bcl-x(L). Anal Biochem\u20082002; 307: 70\u20135.","DOI":"10.1016\/S0003-2697(02)00028-3"},{"key":"2022061700424228400_B20","doi-asserted-by":"crossref","unstructured":"Wang ZX. An exact mathematical expression for describing competitive binding of two different ligands to a protein molecule. FEBS Lett\u20081995; 360: 111\u20134.","DOI":"10.1016\/0014-5793(95)00062-E"},{"key":"2022061700424228400_B21","doi-asserted-by":"crossref","unstructured":"Elmore SW, Oost TK, Park CM. Inhibitors of anti-apoptotic proteins for cancer. Annual Reports in Medicinal Chemistry\u20082005; 40: 245\u201362.","DOI":"10.1016\/S0065-7743(05)40016-0"},{"key":"2022061700424228400_B22","doi-asserted-by":"crossref","unstructured":"Zhai D, Jin C, Satterthwait AC, Reed JC. Comparison of chemical inhibitors of antiapoptotic Bcl-2-family proteins. Cell Death Differ\u20082006; 13: 1419\u201321.","DOI":"10.1038\/sj.cdd.4401937"},{"key":"2022061700424228400_B23","doi-asserted-by":"crossref","unstructured":"Nguyen M, Marcellus RC, Roulston A, et al. Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis. Proc Natl Acad Sci U S A\u20082007; 104: 19512\u20137.","DOI":"10.1073\/pnas.0709443104"},{"key":"2022061700424228400_B24","doi-asserted-by":"crossref","unstructured":"Harada H, Quearry B, Ruiz-Vela A, Korsmeyer SJ. Survival factor-induced extracellular signal-regulated kinase phosphorylates BIM, inhibiting its association with BAX and proapoptotic activity. Proc Natl Acad Sci U S A\u20082004; 101: 15313\u20137.","DOI":"10.1073\/pnas.0406837101"},{"key":"2022061700424228400_B25","doi-asserted-by":"crossref","unstructured":"Certo M, Del Gaizo Moore V, Nishino M, et al. Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell\u20082006; 9: 351\u201365.","DOI":"10.1016\/j.ccr.2006.03.027"},{"key":"2022061700424228400_B26","doi-asserted-by":"crossref","unstructured":"Lin X, Morgan-Lappe S, Huang X, et al. \u201cSeed\u201d analysis of off-target siRNAs reveals an essential role of Mcl-1 in resistance to the small-molecule Bcl-2\/Bcl-X(L) inhibitor ABT-737. Oncogene\u20082007; 26: 3972\u20139.","DOI":"10.1038\/sj.onc.1210166"},{"key":"2022061700424228400_B27","doi-asserted-by":"crossref","unstructured":"Arun B, Frenkel EP. Topoisomerase I inhibition with topotecan: pharmacologic and clinical issues. Expert Opin Pharmacother\u20082001; 2: 491\u2013505.","DOI":"10.1517\/14656566.2.3.491"},{"key":"2022061700424228400_B28","doi-asserted-by":"crossref","unstructured":"Ikegami T, Matsuzaki Y, Al Rashid M, Ceryak S, Zhang Y, Bouscarel B. Enhancement of DNA topoisomerase I inhibitor-induced apoptosis by ursodeoxycholic acid. Mol Cancer Ther\u20082006; 5: 68\u201379.","DOI":"10.1158\/1535-7163.MCT-05-0107"},{"key":"2022061700424228400_B29","doi-asserted-by":"crossref","unstructured":"Zhang H, Nimmer PM, Tahir SK, et al. Bcl-2 family proteins are essential for platelet survival. Cell Death Differ\u20082007; 14: 943\u201351.","DOI":"10.1038\/sj.cdd.4402081"},{"key":"2022061700424228400_B30","doi-asserted-by":"crossref","unstructured":"Kirkin V, Joos S, Zornig M. The role of Bcl-2 family members in tumorigenesis. Biochim Biophys Acta\u20082004; 1644: 229\u201349.","DOI":"10.1016\/j.bbamcr.2003.08.009"},{"key":"2022061700424228400_B31","doi-asserted-by":"crossref","unstructured":"Chauhan D, Velankar M, Brahmandam M, et al. A novel Bcl-2\/Bcl-X(L)\/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma. Oncogene\u20082007; 26: 2374\u201380.","DOI":"10.1038\/sj.onc.1210028"},{"key":"2022061700424228400_B32","doi-asserted-by":"crossref","unstructured":"Maurer U, Charvet C, Wagman AS, Dejardin E, Green DR. Glycogen synthase kinase-3 regulates mitochondrial outer membrane permeabilization and apoptosis by destabilization of MCL-1. Mol Cell\u20082006; 21: 749\u201360.","DOI":"10.1016\/j.molcel.2006.02.009"},{"key":"2022061700424228400_B33","doi-asserted-by":"crossref","unstructured":"Cheng EH, Wei MC, Weiler S, et al. BCL-2, BCL-X(L) sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis. Mol Cell\u20082001; 8: 705\u201311.","DOI":"10.1016\/S1097-2765(01)00320-3"},{"key":"2022061700424228400_B34","doi-asserted-by":"crossref","unstructured":"Zong WX, Lindsten T, Ross AJ, MacGregor GR, Thompson CB. BH3-only proteins that bind pro-survival Bcl-2 family members fail to induce apoptosis in the absence of Bax and Bak. Genes Dev\u20082001; 15: 1481\u20136.","DOI":"10.1101\/gad.897601"},{"key":"2022061700424228400_B35","doi-asserted-by":"crossref","unstructured":"Jazirehi AR, Huerta-Yepez S, Cheng G, Bonavida B. Rituximab (chimeric anti-CD20 monoclonal antibody) inhibits the constitutive nuclear factor-\u03baB signaling pathway in non-Hodgkin's lymphoma B-cell lines: role in sensitization to chemotherapeutic drug-induced apoptosis. Cancer Res\u20082005; 65: 264\u201376.","DOI":"10.1158\/0008-5472.264.65.1"},{"key":"2022061700424228400_B36","doi-asserted-by":"crossref","unstructured":"Vega MI, Jazirehi AR, Huerta-Yepez S, Bonavida B. Rituximab-induced inhibition of YY1 and Bcl-xL expression in Ramos non-Hodgkin's lymphoma cell line via inhibition of NF-\u03ba B activity: role of YY1 and Bcl-xL in Fas resistance and chemoresistance, respectively. J Immunol\u20082005; 175: 2174\u201383.","DOI":"10.4049\/jimmunol.175.4.2174"},{"key":"2022061700424228400_B37","doi-asserted-by":"crossref","unstructured":"Wobser M, Voigt H, Eggert AO, et al. Bcl-2 expression in rituximab refractory cutaneous B-cell lymphoma. Br J Cancer\u20082007; 96: 1540\u20133.","DOI":"10.1038\/sj.bjc.6603762"},{"key":"2022061700424228400_B38","doi-asserted-by":"crossref","unstructured":"Marcus R, Hagenbeek A. The therapeutic use of rituximab in non-Hodgkin's lymphoma. Eur J Haematol\u20082007; 78: 5\u201314.","DOI":"10.1111\/j.1600-0579.2004.00340.x-i1"},{"key":"2022061700424228400_B39","doi-asserted-by":"crossref","unstructured":"Qin JZ, Ziffra J, Stennett L, et al. Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells. Cancer Res\u20082005; 65: 6282\u201393.","DOI":"10.1158\/0008-5472.CAN-05-0676"},{"key":"2022061700424228400_B40","doi-asserted-by":"crossref","unstructured":"Fernandez Y, Verhaegen M, Miller TP, et al. Differential regulation of noxa in normal melanocytes and melanoma cells by proteasome inhibition: therapeutic implications. Cancer Res\u20082005; 65: 6294\u2013304.","DOI":"10.1158\/0008-5472.CAN-05-0686"},{"key":"2022061700424228400_B41","doi-asserted-by":"crossref","unstructured":"Perez-Galan P, Roue G, Villamor N, Montserrat E, Campo E, Colomer D. The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status. Blood\u20082006; 107: 257\u201364.","DOI":"10.1182\/blood-2005-05-2091"},{"key":"2022061700424228400_B42","doi-asserted-by":"crossref","unstructured":"Voortman J, Checinska A, Giaccone G, Rodriguez JA, Kruyt FA. Bortezomib, but not cisplatin, induces mitochondria-dependent apoptosis accompanied by up-regulation of noxa in the non-small cell lung cancer cell line NCI-H460. Mol Cancer Ther\u20082007; 6: 1046\u201353.","DOI":"10.1158\/1535-7163.MCT-06-0577"},{"key":"2022061700424228400_B43","doi-asserted-by":"crossref","unstructured":"Podar K, Gouill SL, Zhang J, et al. A pivotal role for Mcl-1 in bortezomib-induced apoptosis. Oncogene\u20082008; 27: 721\u201331.","DOI":"10.1038\/sj.onc.1210679"},{"key":"2022061700424228400_B44","doi-asserted-by":"crossref","unstructured":"Gomez-Bougie P, Wuilleme-Toumi S, Menoret E, et al. Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma. Cancer Res\u20082007; 67: 5418\u201324.","DOI":"10.1158\/0008-5472.CAN-06-4322"},{"key":"2022061700424228400_B45","doi-asserted-by":"crossref","unstructured":"Mason KD, Carpinelli MR, Fletcher JI, et al. Programmed anuclear cell death delimits platelet life span. Cell\u20082007; 128: 1173\u201386.","DOI":"10.1016\/j.cell.2007.01.037"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/68\/9\/3421\/2602916\/3421.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/68\/9\/3421\/2602916\/3421.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,17]],"date-time":"2023-05-17T22:29:40Z","timestamp":1684362580000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/68\/9\/3421\/543391\/ABT-263-A-Potent-and-Orally-Bioavailable-Bcl-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,5,1]]},"references-count":45,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2008,5,1]]},"published-print":{"date-parts":[[2008,5,1]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-07-5836","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/0008-5472.c.6498161.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.6498161","asserted-by":"object"}],"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/0008-5472.22376333","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22376333.v1","asserted-by":"object"}]},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,5,1]]}}}